Comparison of efficacy of Sodium Valproate versus Levetiracetam in Status Epilepticus

Comparison of efficacy of Sodium Valproate versus Levetiracetam in Status Epilepticus A single-centre, randomised control trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040689

Enrollment

104

Registered

2022-02-28

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G00-G99- Diseases of the nervous system

Interventions

Control Intervention1: Levetiracetam: Group A: Receives IV Levetiracetam loading over 15 minutes as a first line antiepileptic drug therapy Control Intervention2: Sodium Valproate: Group B: Rec

Eligibility

Inclusion criteria

Inclusion criteria: a. Any child between age groups, above 1 years and up to 15 years of age presenting to paediatric emergency department with status epilepticus or admitted in Paediatric department of AIIMS Patna developing status epilepticus.

Exclusion criteria

Exclusion criteria: a. Child with suspected or proven hepatic dysfunction [sodium valproate is hepatotoxic) b. Child with known case of inborn error of metabolism c. Child with known allergy to test drugs

Design outcomes

Primary

Measure	Time frame
Control/Termination of the seizure eventTimepoint: At 15 minutes,at 30 minutes	—

Secondary

Measure	Time frame
Duration for the termination of the seizure, Duration of mechanical ventilation, need of vasopressor/inotrope support, Level of maximum therapy neededTimepoint: 12hrs,24 hrs,48hrs	—

Countries

India

Contacts

Public ContactGiridhar Mf

AIIMS PATNA

lokeshdoc@yahoo.com9631638095

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026